Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.153
Sell
RSI(14)
34.226
Neutral
STOCH(KDJ)(9,3,3)
29.239
Buy
ATR(14)
0.500
High Vlolatility
CCI(14)
-73.997
Neutral
Williams %R
85.093
Oversold
TRIX(12,20)
-0.909
Sell
StochRSI(14)
100.000
Buy
Search
Kalaris Therapeutics Inc
KLRSAdd to Watchlist
3.510USD
+0.030+0.86%
Close 07-31 16:00（ET）Quotes delayed by 15 min
80.70MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey ChartIntraday
1m
30m
1h
D
W
M
D
Today
+0.86%
5 Days
-5.90%
1 Month
-22.52%
6 Months
-60.47%
Year to Date
-58.41%
1 Year
+30.48%
Key Figures
3.430Open
3.610High
71.95KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.31%Turnover Ratio
3.480Prev. Close
3.400Low
145.20KTurnover
LossP/E Static
1.18P/B
0.00%Div Yield TTM
-41.43%ROA
11.88052wk High
0.82Volume Ratio
-58.77MNet Profit
22.99MShares
-0.7871EPS TTM
0.14Beta
-66.60%ROE
2.14052wk Low
6.03%Amplitude
--Gross Margin
80.70MMarket Cap
-3.77Reward/Risk
6.68%Risk Rate
TradingKey Stock Score of Kalaris Therapeutics Inc
Currency: USD Updated: 2026-07-31Key Insights
Kalaris Therapeutics Inc's fundamentals are relatively very healthy, and its growth potential is significant.Its valuation is considered fairly valued, ranking 97 out of 385 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 17.86.In the medium term, the stock price is expected to trend down.Despite a very weak stock market performance over the past month, the company shows strong technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Kalaris Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Kalaris Therapeutics Inc Highlights
StrengthsRisks
Kalaris Therapeutics, Inc., formerly AlloVir, Inc., is a clinical-stage biopharmaceutical company engaged in the development and commercialization of treatments for prevalent retinal diseases. The Company is focused on the development of TH103, a differentiated anti-vascular endothelial growth factor (VEGF) investigational therapy. TH103 is a fully humanized, recombinant fusion protein that acts against VEGF as a decoy receptor and has been specifically engineered for potentially improved VEGF inhibition and longer retention in the retina. TH103 is being evaluated in an ongoing, Phase I clinical trial for the treatment of neovascular age-related macular degeneration (nAMD), with plans to develop TH103 for additional neovascular and exudative diseases of the retina such as diabetic macular edema (DME), and retinal vein occlusion (RVO).
Undervalued
The company’s latest PE is -4.46, at a low 3-year percentile range.
Held by James Simons
Star Investor James Simons holds 0.00 shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of -0.49.
Analyst Rating
Based on
9
analysts
Buy
Current Rating
17.857
Target Price
+425.21%
Upside Space
Kalaris Therapeutics Inc News
More news coming soon, stay tuned...
Earnings Forecast
Analyst Rating
Based on
9
analysts
Buy
Current Rating
17.857
Target Price
+425.21%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
Kalaris Therapeutics Inc
KLRS
9
Beigene Ltd
ONC
28
argenx SE
ARGX
26
Ionis Pharmaceuticals Inc
IONS
26
IQVIA Holdings Inc
IQV
25
Insmed Inc
INSM
23
1
2
3
...
99
Indicators
Moving Average
Indicators
Value
Direction
MA5
3.462
Buy
MA10
3.707
Sell
MA20
4.149
Sell
MA50
4.412
Sell
MA100
5.306
Sell
MA200
6.544
Sell
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Kalaris Therapeutics Inc Info
Kalaris Therapeutics, Inc., formerly AlloVir, Inc., is a clinical-stage biopharmaceutical company engaged in the development and commercialization of treatments for prevalent retinal diseases. The Company is focused on the development of TH103, a differentiated anti-vascular endothelial growth factor (VEGF) investigational therapy. TH103 is a fully humanized, recombinant fusion protein that acts against VEGF as a decoy receptor and has been specifically engineered for potentially improved VEGF inhibition and longer retention in the retina. TH103 is being evaluated in an ongoing, Phase I clinical trial for the treatment of neovascular age-related macular degeneration (nAMD), with plans to develop TH103 for additional neovascular and exudative diseases of the retina such as diabetic macular edema (DME), and retinal vein occlusion (RVO).
Ticker SymbolKLRS
CompanyKalaris Therapeutics Inc
CEOOxtoby (Andrew)
Websitehttps://kalaristx.com/
Shareholders
Related Instruments
-0.53%
+0.27%
-0.92%
-2.51%
+0.32%
-1.45%
-0.64%
-0.82%
-8.79%
+0.52%
+0.68%
-0.95%
-0.71%
+0.44%
-1.08%
+3.29%
0.00%
+1.30%
-0.90%
-2.15%Popular Instruments
52378.000
+109.000 (+0.21%)
28160.900
-37.600 (-0.13%)
7475.100
+30.800 (+0.41%)
14749.000
-90.000 (-0.61%)
62852.000
-742.000 (-1.17%)
6365.400
-1.000 (-0.02%)
85.934
+2.764 (+3.32%)
308.910
-24.520 (-7.35%)
200.750
+5.710 (+2.93%)
4041.430
-61.400 (-1.50%)
FAQs
What is the current price of Kalaris Therapeutics Inc (KLRS)?
The current price of Kalaris Therapeutics Inc (KLRS) is 3.51.
What is the symbol of Kalaris Therapeutics Inc?
The ticker symbol of Kalaris Therapeutics Inc is KLRS.
What is the 52-week high of Kalaris Therapeutics Inc?
The 52-week high of Kalaris Therapeutics Inc is 11.88.
What is the 52-week low of Kalaris Therapeutics Inc?
The 52-week low of Kalaris Therapeutics Inc is 2.14.
What is the market capitalization of Kalaris Therapeutics Inc?
The market capitalization of Kalaris Therapeutics Inc is 80.70M.
Is Kalaris Therapeutics Inc (KLRS) currently rated as Buy, Hold, or Sell?
According to analysts, Kalaris Therapeutics Inc (KLRS) has an overall rating of Buy, with a price target of 17.86.
What is the Earnings Per Share (EPS TTM) of Kalaris Therapeutics Inc (KLRS)?
The Earnings Per Share (EPS TTM) of Kalaris Therapeutics Inc (KLRS) is -2.85.